Other studies report a mesenchymal stromal cell-mediated decrease of reactive oxygen species (ROS) concentrations in CML LSCs or production of FGF2 by mesenchymal stromal cell increases TKI-resistance of CML LSCs [51, 52]. This evidence concerns the gene FGF2 and chronic myelogenous leukemia, BCR-ABL1 positive.